Melinta Therapeutics Receives Positive CHMP Opinion for Vabomere™ (meropenem and vaborbactam)

• Recommended to be approved for treatment of:
• Complicated intra-abdominal (cIAI) and urinary tract infections (cUTI) –
• Hospital-acquired pneumonia including ventilator associated pneumonia (HAP/VAP) –
• Bacteraemia that occurs in association with any of these infections –
• Infections due to aerobic Gram-negative organisms where treatment options are limited-

NEW HAVEN, Conn., Sept. 21, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Vabomere™ (meropenem and vaborbactam) for approval as a treatment for adult patients with complicated intra-abdominal (cIAI) and urinary tract infections (cUTI), hospital-acquired pneumonia including ventilator associated pneumonia (HAP/VAP), bacteraemia that occurs in association with any of these infections, and infections due to aerobic Gram-negative organisms where treatment options are limited.